RxSight, Inc. (NASDAQ:RXST) Insider Sells $151,962.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,070,898.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Stock Up 1.8 %

RXST stock traded up $0.89 during mid-day trading on Monday, reaching $49.43. 436,551 shares of the stock traded hands, compared to its average volume of 484,350. The firm has a market capitalization of $1.83 billion, a PE ratio of -38.72 and a beta of 1.22. The business has a 50-day moving average of $51.15 and a two-hundred day moving average of $53.88. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The firm had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. During the same quarter last year, the firm posted ($0.40) EPS. The company’s revenue was up 67.6% on a year-over-year basis. On average, equities research analysts anticipate that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Stifel Nicolaus cut their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Oppenheimer decreased their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Finally, BTIG Research raised their target price on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, July 15th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $60.14.

Hedge Funds Weigh In On RxSight

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC grew its position in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the last quarter. Quest Partners LLC acquired a new position in shares of RxSight during the second quarter valued at about $41,000. Larson Financial Group LLC bought a new stake in shares of RxSight in the first quarter valued at about $51,000. Amalgamated Bank grew its position in RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after buying an additional 207 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in RxSight during the second quarter valued at about $156,000. Institutional investors own 78.78% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.